RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics Authorizes Up To $200M In Common Stock Sales Through Jefferies
Design Therapeutics Files Prospectus For Offering $300M Mixed Shelf
Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.